What is BTIG's price target for AVTE?

BTIG's latest stated price target for Aerovate Therapeutics Inc. (AVTE) is $27, from its action on Dec 6, 2022.

What is BTIG's rating on AVTE?

BTIG rates AVTE Neutral, a neutral rating, as of Jun 17, 2024.

When did BTIG last change its view on AVTE?

On Jun 17, 2024, BTIG downgrades to Neutral from Buy.

BTIG AVTE price target and rating history

Aerovate Therapeutics Inc. (AVTE) · Health Care

BTIG rates Aerovate Therapeutics Inc. (AVTE) Neutral with a $27 price target, as of its latest action on Jun 17, 2024. It has published 4 rating actions on AVTE since February 2022, including 1 upgrade and 2 downgrades.

Current rating: Neutral
Price target: $27
Median target, all firms: Too few
Actions on AVTE: 4

BTIG price target on AVTE

BTIG price target on AVTE, each point a stated target, February 2022 to December 2022.

Every BTIG rating on AVTE

Jun 17, 2024
DowngradeBTIG downgrades to Neutral from Buy
Dec 6, 2022
UpgradeBTIG upgrades to Buy from Neutral, price target $27
Aug 16, 2022
DowngradeBTIG downgrades to Neutral from Buy
Feb 11, 2022
InitiateBTIG starts coverage at Buy, price target $24

Questions about BTIG and AVTE

What is BTIG's price target for AVTE?: BTIG's latest stated price target for Aerovate Therapeutics Inc. (AVTE) is $27, from its action on Dec 6, 2022.
What is BTIG's rating on AVTE?: BTIG rates AVTE Neutral, a neutral rating, as of Jun 17, 2024.
When did BTIG last change its view on AVTE?: On Jun 17, 2024, BTIG downgrades to Neutral from Buy.

More AVTE rating histories

Wedbush3

All BTIG ratings AVTE news and filings Every analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.